American Shared Hospital Services (NYSE American: AMS), a leading provider of stereotactic radiosurgery equipment and advanced radiation therapy cancer treatment services, today announced that it will hold a conference call to discuss its first quarter 2026 financial results on May 14, 2026, at 12:00 PM ET. The financial results press release will be issued before the market opens on the same day.
The teleconference will be accessible to domestic callers at 1-844-413-3972 and international callers at 1-412-317-5776, with participants asked to join at least 10 minutes prior to the start and request the American Shared Hospital Services call. A simultaneous webcast can be accessed through the Company's website at www.ashs.com or directly via this link. A replay will be available from May 14 through May 21, 2026, by dialing 1-855-669-9658 or 1-412-317-0088 with access code 6753554, and will also be archived on the Company's website.
The announcement comes as AMS continues to expand its turnkey solutions for cancer treatment centers, health systems, and cancer networks across North and South America. The company works closely with partners to develop and grow cancer service lines, providing integrated care in local settings. Under health system partnerships, AMS and its partners share capital investment costs and profitability based on ownership interests. This model aims to reduce financial barriers for healthcare providers while expanding access to advanced treatments like Gamma Knife, proton therapy, and other radiation therapies.
The upcoming earnings call will likely shed light on the company's financial performance amidst evolving market conditions. The safe harbor statement in the press release notes that forward-looking statements involve risks including economic conditions, compliance with debt covenants, variability of quarterly results, changes in CMS reimbursement rates, and the timing and financing of business expansions. These factors could influence the company's growth trajectory in the competitive cancer treatment landscape.
For investors and industry observers, the conference call provides an opportunity to assess AMS's progress in its equipment leasing and direct patient care segments. The company's focus on stereotactic radiosurgery—a non-invasive technique for treating tumors—positions it in a growing field where demand for precision oncology is rising. The call may also address the impact of recent acquisitions or operational challenges that could affect future performance.
The Q1 2026 results are expected to reflect the company's ability to navigate regulatory and reimbursement environments while maintaining its service quality. As cancer treatment paradigms shift toward more localized and advanced technologies, AMS's business model of shared investments with health systems could offer a scalable path for adoption. The earnings discussion will be closely watched by stakeholders seeking clarity on revenue trends, contract renewals, and strategic initiatives.
